Innovent Biologics' Q2 Revenue Surges 50% on Non-Small Cell Lung Cancer Treatment Sales Innovent Biologics' (HKG:1801) second-quarter revenue surged 50% year over year to top 2 billion yuan, according...
Source LinkInnovent Biologics' Q2 Revenue Surges 50% on Non-Small Cell Lung Cancer Treatment Sales Innovent Biologics' (HKG:1801) second-quarter revenue surged 50% year over year to top 2 billion yuan, according...
Source Link
Comments